MRX-2843 with osimertinib for EGFR-mutant lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1 study tests whether combining MRX-2843 with osimertinib can help control advanced lung cancer that has specific EGFR gene changes. It is designed to find the safest dose and check early signs of tumor response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (metastatic) non-small cell lung cancer with an EGFR-activating mutation in exons 19 or 21
- Your general health/function score is ECOG 0 to 2 (you can do self-care, with limited activity if any)
- For the group that measures response, you have a measurable tumor spot at least 1–2 cm on imaging or exam
- You can take study pills by mouth, and your blood counts and liver/kidney tests are within required ranges
- If you could become pregnant (or have a partner who could), you must use reliable birth control during the study and for a set time after
- You can’t have certain recent chemotherapy/radiation, untreated brain symptoms, or lung scarring/inflammation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests osimertinib combined with tegavivint as the first treatment for metastatic (stage IV) non-small cell lung cancer (NSCLC) with certain EGFR gene mutations. It aims to find the safest dose and see how well the combination can control cancer and side effects.
This Phase 2 study tests osimertinib (a targeted lung cancer pill) in people with advanced non-small cell lung cancer (NSCLC) whose tumors have an EGFR exon 20 insertion. It aims to see how well osimertinib works for this specific EGFR mutation and how safe it is.
This trial tests a combination of three targeted drugs for people with advanced non-small cell lung cancer that has a specific EGFR gene change. The goal is to see if the combination can control the cancer when previous treatments have stopped working.
This Phase 3 trial tests whether starting osimertinib with or without bevacizumab helps people with advanced EGFR-mutant lung cancer live longer and control the cancer better. Your EGFR mutation test result and past treatments are key to whether you can join.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
Hear when a new Advanced Lung Non-Small Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.